Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25159693
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Peering into the pharmaceutical "pipeline": investigational drugs, clinical
trials, and industry priorities
#MMPMID25159693
Fisher JA
; Cottingham MD
; Kalbaugh CA
Soc Sci Med
2015[Apr]; 131
(?): 322-30
PMID25159693
show ga
In spite of a growing literature on pharmaceuticalization, little is known about
the pharmaceutical industry's investments in research and development (R&D).
Information about the drugs being developed can provide important context for
existing case studies detailing the expanding--and often problematic--role of
pharmaceuticals in society. To access the pharmaceutical industry's pipeline, we
constructed a database of drugs for which pharmaceutical companies reported
initiating clinical trials over a five-year period (July 2006-June 2011),
capturing 2477 different drugs in 4182 clinical trials. Comparing drugs in the
pipeline that target diseases in high-income and low-income countries, we found
that the number of drugs for diseases prevalent in high-income countries was 3.46
times higher than drugs for diseases prevalent in low-income countries. We also
found that the plurality of drugs in the pipeline was being developed to treat
cancers (26.2%). Interpreting our findings through the lens of
pharmaceuticalization, we illustrate how investigating the entire drug
development pipeline provides important information about patterns of
pharmaceuticalization that are invisible when only marketed drugs are considered.
free
free
free
